The 10-second takeaway
For the quarter ended June 30 (Q4), Molex missed estimates on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue shrank and GAAP earnings per share dropped.
Margins shrank across the board.
Molex reported revenue of $858.5 million. The 13 analysts polled by S&P Capital IQ anticipated sales of $878.8 million on the same basis. GAAP reported sales were 6.0% lower than the prior-year quarter's $913.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.35. The 14 earnings estimates compiled by S&P Capital IQ forecast $0.38 per share. GAAP EPS of $0.40 for Q4 were 9.1% lower than the prior-year quarter's $0.44 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 30.0%, 80 basis points worse than the prior-year quarter. Operating margin was 11.2%, 120 basis points worse than the prior-year quarter. Net margin was 8.4%, 10 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $907.6 million. On the bottom line, the average EPS estimate is $0.43.
Next year's average estimate for revenue is $3.65 billion. The average EPS estimate is $1.73.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 134 members out of 149 rating the stock outperform, and 15 members rating it underperform. Among 43 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 41 give Molex a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Molex is hold, with an average price target of $27.21.
Can your retirement portfolio provide you with enough income to last? You'll need more than Molex. Learn about crafting a smarter retirement plan in "The Shocking Can't-Miss Truth About Your Retirement." Click here for instant access to this free report.
- Add Molex to My Watchlist.